Cargando…
Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study
BACKGROUND: The long-term risks and time trends of subsequent primary neoplasms (SPNs) among Ewing (ES) and osteosarcoma (OS) survivors are not fully understood. METHODS: We performed a nationwide study of all ES and OS patients identified in the Swedish Cancer Registry from 1958 to 2015 with up to...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156510/ https://www.ncbi.nlm.nih.gov/pubmed/32066914 http://dx.doi.org/10.1038/s41416-020-0748-3 |
_version_ | 1783522223414312960 |
---|---|
author | Hesla, Asle Charles Discacciati, Andrea Tsagkozis, Panagiotis Smedby, Karin E. |
author_facet | Hesla, Asle Charles Discacciati, Andrea Tsagkozis, Panagiotis Smedby, Karin E. |
author_sort | Hesla, Asle Charles |
collection | PubMed |
description | BACKGROUND: The long-term risks and time trends of subsequent primary neoplasms (SPNs) among Ewing (ES) and osteosarcoma (OS) survivors are not fully understood. METHODS: We performed a nationwide study of all ES and OS patients identified in the Swedish Cancer Registry from 1958 to 2015 with up to 58 years of follow-up. The risk of SPN was compared with that of the general population using standardised incidence ratios (SIRs) and absolute excess risks (AERs). RESULTS: One hundred and fifteen SPNs were diagnosed among 1779 patients with ES or OS, yielding an overall SIR of 2.3 (95% confidence interval (CI), 1.9–2.7). The risk remained significantly increased in the latest treatment era (SIR(2000-2015) 2.0; 95% CI, 1.1–3.5). The highest absolute excess risks (AER) was due to breast cancer (AER 15.2/10,000 person-years; 95% CI, 5.0–29.8) followed by female genital malignancies (AER 9.5/10,000 person-years; 95% CI, 2.4–21.5). The excess breast cancer risk among ES survivors was noted also after 30 years of follow-up with 127 extra breast cancers/10,000 person-years (95% CI, 6.6–419). CONCLUSIONS: Breast- and female genital malignancies contribute most to the excess risk of SPN among ES and OS survivors. Importantly, excess risks did not decline over calendar time or long-term follow-up. |
format | Online Article Text |
id | pubmed-7156510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-71565102021-02-18 Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study Hesla, Asle Charles Discacciati, Andrea Tsagkozis, Panagiotis Smedby, Karin E. Br J Cancer Article BACKGROUND: The long-term risks and time trends of subsequent primary neoplasms (SPNs) among Ewing (ES) and osteosarcoma (OS) survivors are not fully understood. METHODS: We performed a nationwide study of all ES and OS patients identified in the Swedish Cancer Registry from 1958 to 2015 with up to 58 years of follow-up. The risk of SPN was compared with that of the general population using standardised incidence ratios (SIRs) and absolute excess risks (AERs). RESULTS: One hundred and fifteen SPNs were diagnosed among 1779 patients with ES or OS, yielding an overall SIR of 2.3 (95% confidence interval (CI), 1.9–2.7). The risk remained significantly increased in the latest treatment era (SIR(2000-2015) 2.0; 95% CI, 1.1–3.5). The highest absolute excess risks (AER) was due to breast cancer (AER 15.2/10,000 person-years; 95% CI, 5.0–29.8) followed by female genital malignancies (AER 9.5/10,000 person-years; 95% CI, 2.4–21.5). The excess breast cancer risk among ES survivors was noted also after 30 years of follow-up with 127 extra breast cancers/10,000 person-years (95% CI, 6.6–419). CONCLUSIONS: Breast- and female genital malignancies contribute most to the excess risk of SPN among ES and OS survivors. Importantly, excess risks did not decline over calendar time or long-term follow-up. Nature Publishing Group UK 2020-02-18 2020-04-14 /pmc/articles/PMC7156510/ /pubmed/32066914 http://dx.doi.org/10.1038/s41416-020-0748-3 Text en © The Author(s), under exclusive licence to Cancer Research UK 2020 https://creativecommons.org/licenses/by/4.0/Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
spellingShingle | Article Hesla, Asle Charles Discacciati, Andrea Tsagkozis, Panagiotis Smedby, Karin E. Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study |
title | Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study |
title_full | Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study |
title_fullStr | Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study |
title_full_unstemmed | Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study |
title_short | Subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study |
title_sort | subsequent primary neoplasms among bone sarcoma survivors; increased risks remain after 30 years of follow-up and in the latest treatment era, a nationwide population-based study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156510/ https://www.ncbi.nlm.nih.gov/pubmed/32066914 http://dx.doi.org/10.1038/s41416-020-0748-3 |
work_keys_str_mv | AT heslaaslecharles subsequentprimaryneoplasmsamongbonesarcomasurvivorsincreasedrisksremainafter30yearsoffollowupandinthelatesttreatmenteraanationwidepopulationbasedstudy AT discacciatiandrea subsequentprimaryneoplasmsamongbonesarcomasurvivorsincreasedrisksremainafter30yearsoffollowupandinthelatesttreatmenteraanationwidepopulationbasedstudy AT tsagkozispanagiotis subsequentprimaryneoplasmsamongbonesarcomasurvivorsincreasedrisksremainafter30yearsoffollowupandinthelatesttreatmenteraanationwidepopulationbasedstudy AT smedbykarine subsequentprimaryneoplasmsamongbonesarcomasurvivorsincreasedrisksremainafter30yearsoffollowupandinthelatesttreatmenteraanationwidepopulationbasedstudy |